Leon Nanodrugs and Evonik Canada have completed an indepedent feasibility study evaluating Leon's FR-JET technology.
To assess the potential of Leon's platform, Evonik's team of nanoformulation experts tested the technology, finding that it had an "exceptional" capacity to manufacture nanoparticles for precision drug delivery.
The team at Evonik also found that FR-JET worked efficiently and consistently, highlighting its potential in the field of next-generation drug delivery.
The testing process
To test the functionality of FR-JET, multiple drug-loaded and placebo lipid-based and non-lipid nanoparticle formulations were prepared using the technology.
The formulations inlcuded both lipid nanoparticles and polymer-based systems.
It was noted that the FR-JET system had a broad operating window, which is essential when developing nanoparticle formulations, according to Leon Nanodrugs.
FR-JET was also deemed scalable, highlighting its potential as a small-scale research tool, as well as a system for large-scale commercial production.
“The diversity of API moieties and delivery systems seen in today's market means that manufacturing platforms must be versatile," stated Health of Growth Projects, Health Care at Evonik, Dr Andrea Engel.
"This ensures the right match between a drug and its production process, which can heighten a drug’s performance and streamline production.”
Nanoparticles "shape the future" of drug delivery
Nanoparticles are being increasingly recognised for their ability to support precision drug delivery, and Leon Nanodrugs believes that they are a crucial component of next-generation drug delivery systems.
With significant advancements occurring in the cell and gene therapy (CGT) space, businesses will increasingly rely on non-viral nanoparticle delivery systems to develop their therapy.
However, there are currently some hurdles to overcome in the nanoparticle manufacturing space.
Therefore, Leon Nanodrugs has set out to address these issues with its GMP-compliant FR-JET nanoencapsulation technology, which utilises highly controlled mixing conditions to enable rapid process transfer and consistent product quality at both high and low flow rates.
According to the company, its nanoencapsulation technology can support drug developers in nanoencapsulating their APIs from the R&D stage to commercial production.
Dr Setu Kasera, Chief Scientific Officer at Leon, concluded: “We are thrilled to have our technology validated by such a reputable industry partner. The results not only underscore the robustness of our nanoparticle manufacturing process but also pave the way for future advancements in drug delivery systems.”